[Endoscopy in patients receiving anticoagulation or antiplatelet therapy].
Drugs that interfere with haemostasis are widely used for thromboembolic diseases and cardiovascular protection. Gastrointestinal bleeding is a well-known complication, and endoscopists are often faced with decisions concerning the safety of endoscopic procedures in these patients. Based on expert opinion and on data from observational studies, we suggest algorithms for the approach to acute and elective procedures based on procedural risk and on risks for thromboembolic episodes.
Kjeldsen
Jens
J
Endoskopiudvalget under Dansk Gastroenterologisk Selskab Odense Universitetshospital, Medicinsk Gastroenterologisk Afdeling S og Kirurgisk Afdeling A, Køge Sygehus, DK-4600 Køge.
Pless
Torsten
T
Meisner
Søren
S
Bytzer
Peter
P
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D016063:Blood Loss, Surgical; D017558:Elective Surgical Procedures; D004630:Emergencies; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011183:Postoperative Complications / Q000139:chemically induced / Q000209:etiology; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology; D015912:Thrombolytic Therapy / Q000009:adverse effects*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors